Do you want to read an article? Please log in or register.
Population-based frequency of ophthalmic adverse events in melanoma, other cancers, and after immune checkpoint inhibitor treatment
Uveitis
Related content
Further Publications
Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience
Br J Ophthalmol
Fortes BH, Liou H, Dalvin LA
doi: 10.1136/bjophthalmol-2020-316970
Further Publications
Ophthalmic immune-related adverse events following anti-CTLA-4 or PD-1 therapy recorded in the American Academy of Ophthalmology IRIS® Registry
Ophthalmology
Sun MM, Kelly SP, Mylavarapu AL, Holland GN, Coleman AL, Yu F, Hsu S, Lum F, Gordon LK
doi: 10.1016/j.ophtha.2020.11.001
Ocular Oncology
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
Eur J Cancer.
Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C
doi: 10.1016/j.ejca.2017.05.038.
RECOMMENDED
Glaucoma and Ocular PressureOcular OncologyRetinal DiseasesSurgery and Intervention
Glaucoma-Related Adverse Events at 10 Years in the Infant Aphakia Treatment Study: A Secondary Analysis of a Randomized Clinical Trial
★ 3
Recommended by
Prof. Dr Ke Yao, Faculty Member
★ 3
Recommended by
Prof. Dr emer. Josef Flammer, Faculty Member
JAMA Ophthalmol
Freedman SF, Beck AD, Nizam A, Vanderveen DK, Plager DA, Morrison DG, Drews-Botsch CD, Lambert SR, Infant Aphakia Treatment Study Group.
doi: 10.1001/jamaophthalmol.2020.5664
Ocular Oncology
Intravitreous Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading
Ophthalmology.
Francis JH, Berry D, Abramson DH, Barker CA, Bergstrom C, Demirci H, Engelbert M, Grossniklaus H, Hubbard B, Iacob CE, Jaben K, Kurli M, Postow MA, Wolchok JD, Kim IK, Wells JR
doi: 10.1016/j.ophtha.2019.09.018.
UveitisFurther Publications
A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis
Sci Rep
Rusche H, Marrani E, Real-Fernandez F, Ponti R, Terzani F, Maccora I, Monasson O, Mastrolia MV, Peroni E, Pagnini I, Cimaz R, Papini AM, Simonini G, Rovero P
doi: 10.1038/s41598-021-95920-9
Uveitis
Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials
Ophthalmology.
Suhler EB, Thorne JE, Mittal M, Betts KA, Tari S, Camez A, Bao Y, Joshi A
doi: 10.1016/j.ophtha.2017.06.017.
Uveitis
Long-term efficacy and tolerability of TNFα inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study
Br J Ophthalmol.
Sharma SM, Damato E, Hinchcliffe AE, Andrews CD, Myint K, Lee R, Dick AD
doi: 10.1136/bjophthalmol-
Ocular Oncology
New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review
Biomedicines
Toro MD, Gozzo L, Tracia L, Cicciù M, Drago F, Bucolo C, Avitabile T, Rejdak R, Nowomiejska K, Zweifel S, Yousef YA, Nazzal R, Romano GL
doi: 10.3390/biomedicines9101311